Sacral Neuromodulation Triumphs Over Conservative Treatment for Refractory Slow-Transit Constipation

In the No.2-Trial, comparing sacral neuromodulation (SNM) to personalized conservative treatment (PCT) for refractory idiopathic slow-transit constipation, SNM demonstrated significant success (53.7%) compared to PCT (3.8%) after six months. SNM patients reported lower constipation severity and fatigue, along with improved quality of life. Serious adverse events were minimal (6 SNM, 2 PCT), supporting SNM as a promising surgical option for refractory slow-transit constipation.